Carnitine supplements for people with chronic kidney disease requiring dialysis

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

The objective of this review is to evaluate the effectiveness and safety of carnitine for the treatment of dialysis-related complications.

This is a protocol.

Health topics:

Kidney disease > End-stage kidney disease > General management

Insurance medicine > Participation > Kidney disease

Published:

10 May 2020

Authors:

Nishioka N, Luo Y, Taniguchi T, Ohnishi T, Kimachi M, Ng RCK, Watanabe N

Primary Review Group:

Kidney and Transplant Group

See the full Review on

the Cochrane Library

►

Print
PDF
Citation
Nishioka N, Luo Y, Taniguchi T, Ohnishi T, Kimachi M, Ng RCK, Watanabe N. Carnitine supplements for people with chronic kidney disease requiring dialysis (Protocol). Cochrane Database of Systematic Reviews 2020, Issue 5. Art. No.: CD013601. DOI: 10.1002/14651858.CD013601.

Don't show again

What role do you identify with the most?

General public, patient, or care giver

Health practitioner

Researcher

Policy Maker

We are collecting information on visitors to our website to ensure Cochrane resources meet the needs of our users. Your data will be anonymised for processing, will be stored securely, and will not be shared with any third parties.